about
Skewed X-chromosome inactivation in sclerodermaHistone deacetylase: a potential therapeutic target for fibrotic disordersDissection of the mechanism of traditional Chinese medical prescription-Yiqihuoxue formula as an effective anti-fibrotic treatment for systemic sclerosis.Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication.The epigenetics of autoimmunity.Intracellular free radical production by peripheral blood T lymphocytes from patients with systemic sclerosis: role of NADPH oxidase and ERK1/2.Methods for the morphological and functional evaluation of microvascular damage in systemic sclerosis.Involvement of collagen-binding heat shock protein 47 in scleroderma-associated fibrosis.Histone deacetylase inhibition and the regulation of cell growth with particular reference to liver pathobiology.Diagnostic and prognostic potential of gene microarrays in rheumatoid arthritis.Role of microRNAs in gastrointestinal smooth muscle fibrosis and dysfunction: novel molecular perspectives on the pathophysiology and therapeutic targeting.Factors associated with gingival inflammation among adults with systemic sclerosis.Histomorphometric analysis of cutaneous remodeling in the early stage of the scleroderma model.Test--retest reliability of Oral Health Impact Profile (OHIP-49) in adults with systemic sclerosisScleroderma, stress and CAM utilization.Factors associated with oral hygiene practices among adults with systemic sclerosis.Biomarkers in systemic sclerosis.Evidence of an antifibrotic effect of immunosuppressive drugs: applications in the treatment of systemic sclerosis.Systematic review: the relationship between interstitial lung diseases and gastro-oesophageal reflux disease.Modulation of fibrosis in systemic sclerosis by nitric oxide and antioxidants.Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with Systemic Sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study.FIZZ1-induced myofibroblast transdifferentiation from adipocytes and its potential role in dermal fibrosis and lipoatrophy.Elevated expression of isopeptide bond cross-links contributes to fibrosis in scleroderma and the healing wounds of tight skin mice.Exercise in systemic sclerosis intensifies systemic inflammation and oxidative stress.Organ involvement in Argentinian systemic sclerosis patients with "late" pattern as compared to patients with "early/active" pattern by nailfold capillaroscopy.Evaluation of the Anterior Segment Parameters of the Patients with Scleroderma.Risk association between scleroderma disease characteristics, periodontitis, and tooth loss.Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring.Assessment of Central Corneal Thickness in Different Subtypes of Systemic Sclerosis.Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression.Association of -318 C/T and +49 A/G cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms with a clinical subset of Italian patients with systemic sclerosis
P2860
Q24644300-6ABD5BF4-9464-4EC9-8036-D624FFF4E6A1Q34257607-916A4C58-D713-44B6-A0FF-6673DD884ABBQ34485231-736B2265-3BC1-45DA-A830-79B3D0B35F11Q34590794-26597485-8C2A-4012-A3F5-F9816B1EC1D6Q34979322-E75479B3-E78D-4C3B-9E0D-AF831C16141BQ35257518-0579959A-DB44-4F20-AEE8-2EE49E9A36E3Q35542989-AD6AD43D-2CDF-4D31-8CB1-FA2B7CA15518Q35862865-2C263246-0949-446C-8DB8-DE5E072A913AQ35893218-E58A44BA-CA7A-4E57-8773-DF1A30CD4E0CQ36252156-35F9A051-B037-48DA-B0B1-286A8FCCCD99Q36775830-F70E10C3-713E-40F3-9EA7-1C9C8B79307DQ37045999-EF71BB30-9D90-4BD2-AA69-5EE5D629F5F4Q37248942-91B1FC40-4E89-496E-8EAE-F63923F972E5Q37430001-29FDE5D5-0BE4-4B3E-AC3B-258C9A244452Q37432445-4EDD0310-1D8D-4487-80A1-0F744FEAFC43Q37705290-CE935D4D-68FF-4D7A-B075-B038EF5140C3Q37730018-2087253B-AAF8-4617-8475-DC832F03B48FQ37754503-C12C983B-A382-46F7-B4BD-B826DB06BC56Q37945729-5D70FCF2-89B4-4673-A250-A09967D5A663Q38909892-439FEF4A-4B13-4090-8851-4547DF812F23Q39966988-8C8D3BF6-E833-422B-A5C4-2C7DAA21C62EQ42044349-6C478515-4BE7-4A11-99D7-24EE278972A7Q42272522-3327F436-3700-4347-ABCE-C55C97FDDDCAQ42466834-02EAAD5F-2B50-4DA7-9A60-FE0C960B8949Q46012346-DEF01EA5-898A-47EB-9F32-BA387A0D8E14Q47596401-CDA0296A-5977-4A2F-B7DB-92EDAF15F579Q49501783-2A088321-782D-4D2F-A0E6-C615062B26CFQ51667290-146FB116-2232-46F4-B2E7-0BC47518BFA8Q53254335-BF845DA2-6C7A-4213-9CAD-D863534E99AEQ55261205-6761F214-B32E-4DF1-BAC9-45129A113048Q56901252-417B3C3E-1789-48E4-ADBD-BB9F0E3404C6
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Systemic sclerosis: current views of its pathogenesis.
@ast
Systemic sclerosis: current views of its pathogenesis.
@en
type
label
Systemic sclerosis: current views of its pathogenesis.
@ast
Systemic sclerosis: current views of its pathogenesis.
@en
prefLabel
Systemic sclerosis: current views of its pathogenesis.
@ast
Systemic sclerosis: current views of its pathogenesis.
@en
P1433
P1476
Systemic sclerosis: current views of its pathogenesis.
@en
P2093
Chris T Derk
Sergio A Jimenez
P304
P356
10.1016/S1568-9972(03)00005-3
P577
2003-06-01T00:00:00Z